Amphotericin B for non-HIV cryptococcal meningitis
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This trial tests the drug amphotericin B for people with cryptococcal meningitis who do not have HIV. The goal is to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You do not have HIV.
- You have been diagnosed with cryptococcal meningitis (a brain infection caused by a fungus).
- You do not have a severely weakened immune system.
- You have not had this infection before, and you are not currently on treatment for it beyond a short period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This study tests a shorter course of an antifungal medicine (fluconazole) for people with HIV who have a low level of a fungus called cryptococcus in their blood. The goal is to see if a shorter treatment works as well and to find the best time to start HIV medicines.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
This trial tests a single high dose of a potent antifungal medicine (liposomal amphotericin B) combined with a modern HIV treatment (B/F/TAF) for people with HIV who have a serious fungal infection called talaromycosis. The goal is to see if this short, powerful treatment works well and is safe.
This study tests whether a combination of two antifungal drugs works well for treating talaromycosis, a serious fungal infection common in people with HIV. The goal is to find a more convenient and effective treatment.
Hear when a new Cryptococcal Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.